Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by alamo07on Jun 05, 2020 12:03pm

121 Views

Post# 31116872

RE:RE:RE:RE:Why IS THIS STOCK FALLING!

I think most here are still in the green. Some don't have time to sit in front of a computer all day and trade stocks. More long term investment happening here. It's the ones that were told to buy shares Friday by McWhirter that got hit the hardest.

Even if we got the bump that was expected I suspect it woulve been a quick fall just like April 2018.

Here we are now with the chance to load up at super low prices. My retirement fund will not suffer from this week.

Bullboard Posts

Victoria Gold: No cyanide detected downstream since mine incident